Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Irbesartan
Drug ID BADD_D01194
Description Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy.[L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy.[L7459] Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.[L7456,L7459] Irbesartan was granted FDA approval on 30 September 1997.[L7456,L7459]
Indications and Usage For the treatment of hypertension, as well as diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. Irbesartan is also used as a second line agent in the treatment of congestive heart failure.
Marketing Status Prescription; Discontinued
ATC Code C09CA04
DrugBank ID DB01029
KEGG ID D00523
MeSH ID D000077405
PubChem ID 3749
TTD Drug ID D00JAU
NDC Product Code 65162-284; 42658-122; 12666-0011; 0024-5851; 71205-452; 50090-4519; 63187-757; 59746-449; 70518-2245; 50090-3244; 33342-049; 29300-212; 31722-161; 68382-300; 33342-048; 70771-1160; 0024-5852; 53747-029; 62332-043; 68554-0005; 46708-440; 71205-082; 50090-3431; 66639-006; 65372-1118; 71335-1826; 53360-1305; 63629-8259; 68180-410; 70771-1161; 0955-1040; 50228-161; 50228-162; 65862-639; 0955-1042; 70518-2211; 42658-121; 71335-0423; 50090-5055; 59746-448; 65162-286; 42419-011; 65862-530; 31722-160; 62332-041; 29300-214; 63187-737; 71335-0071; 0955-1041; 65862-637; 62332-042; 65862-638; 71335-1263; 72189-270; 65162-285; 70518-2685; 68180-411; 46708-872; 50228-160; 43547-375; 70518-2205; 69766-101; 64220-130; 82231-110; 42658-123; 33342-047; 50090-2017; 68382-299; 53360-1303; 59746-447; 31722-729; 62331-054; 31722-162; 65841-156; 55111-082; 71205-404; 63629-5241; 50090-3269; 43547-374; 68382-301; 50090-2978; 71335-1547; 53360-1307; 29300-213; 68180-412; 46708-441; 72189-201; 0024-5850; 61919-793; 31722-731; 46708-439; 72189-205; 70771-1159; 70518-2246; 71335-1244; 43547-376; 15894-0008; 31722-730; 70518-1328; 71205-379
Synonyms Irbesartan | Avapro | Karvea | 2-N-Butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one | Aprovel | SR 47436 | SR-47436 | SR47436 | BMS 186295 | BMS-186295
Chemical Information
Molecular Formula C25H28N6O
CAS Registry Number 138402-11-6
SMILES CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malabsorption07.17.01.001; 14.02.01.0040.000904%
Malaise08.01.01.0030.009948%
Menopausal symptoms21.02.02.002--Not Available
Micturition disorder20.02.02.005--Not Available
Monoparesis17.01.04.011--Not Available
Mood swings19.04.03.001--Not Available
Movement disorder17.01.02.0100.000904%Not Available
Muscle atrophy17.05.03.004; 15.05.03.003--Not Available
Muscle rupture15.05.07.003; 12.01.07.0100.001809%Not Available
Muscle spasms15.05.03.0040.001507%
Muscular weakness17.05.03.005; 15.05.06.0010.000904%
Musculoskeletal pain15.03.04.0070.000904%
Myalgia15.05.02.0010.001809%
Myocardial infarction24.04.04.009; 02.02.02.007--
Myositis15.05.01.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nephropathy20.05.03.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.0030.001206%Not Available
Neuropathy peripheral17.09.03.0030.001206%Not Available
Neutropenia01.02.03.0040.001507%Not Available
Neutrophil count13.01.06.046--Not Available
Ocular hyperaemia06.04.05.0040.000603%Not Available
Oedema14.05.06.010; 08.01.07.0060.000603%Not Available
Oedema peripheral14.05.06.011; 02.05.04.007; 08.01.07.0070.001809%
Oesophagitis07.08.05.001--
Oral mucosal blistering07.05.05.0170.000603%Not Available
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Osteoporosis15.02.03.002; 14.04.04.0020.000603%
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 12 Pages